职称：教授　主任医师

现就职医院：中山大学肿瘤医院

擅长：乳腺癌

袁中玉，男，肿瘤学博士学位，主任医师，中山大学肿瘤医院内科乳腺癌专业组主诊教授，博士研究生导师。现就职于中山大学肿瘤防治中心内科。

专业特长：

从事肿瘤内科治疗的临床工作及抗癌药物研究。特别擅长乳腺癌的内科治疗及研究（包括化学治疗、内分泌治疗、靶向治疗等）。

教育执业经历：

1984年-1989年：安徽医科大学就读

1989年-1997年：安徽合肥西市区人民医院工作

1997年-2000年：安徽医科大学就读硕士生

2000年-2003年：中山大学附属肿瘤医院攻读博士生

2003年至今：中山大学附属肿瘤医院工作

临床科研：

(1) miR-657诱导乳腺癌早期转移的分子机制

(2) 三阴乳腺癌远处转移的分子机制

(3) 可手术三阴乳腺癌标准辅助化疗后卡培他滨节拍化疗的前瞻性随机对照临床研究

(4) 曲妥珠单抗联合化疗或芳香化酶抑制剂一线治疗Luminal B2型复发转移性乳腺癌的多中心、随机、对照临床研究

(5) 神经节苷脂预防乳腺癌患者使用含紫杉类方案辅助化疗所致神经毒性的多中心、前瞻性、随机、安慰剂对照、双盲临床研究

(6) 比卡鲁胺对比化疗一线治疗AR阳性晚期三阴乳腺癌患者的多中心、非劣效性、随机对照临床研究

(7) 盐酸埃克替尼治疗一线化疗失败的复发和/转移性三阴型乳腺癌的单臂、开放II期临床研究

(8) AHST支持下HDC治疗转移性三阴型乳腺癌的Ⅱ期临床研究

(9) 拉帕替尼联合化疗治疗曲妥珠单抗难治性转移性乳腺癌的多中心、Ⅱ期临床研究

学术任职：

广东省健康管理学会乳腺癌专业委员会副主任委员、广东省胸部肿瘤协会乳腺癌专业委员会副主任委员、广东省中医药学会乳腺病专业委员会副主任委员、广东省药学会乳腺科用药专家委员会副主任委员、广东省抗癌协会靶向与个体化治疗专业委员会常委、广东省抗癌协会乳腺癌专业委员会常委。

发表论著：

(1) Qin Tao, Yuan Zhong-Yu, Peng Rou-Jun, Bai Bing Zeng, Yin-Duo Shi, Yan-Xia Teng, Xiao-Yu Liu, Dong-Geng Wang, Shu-Sen(*). Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China., Archives of Medical Science,2015,11(3):544-550.

(2) Yuan Zhong-Yu ,Luo Rong-Zhen, Peng Rou-Jun, Wang Shu-Sen, Xue Cong. High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis.,OncoTargets and herapy,2014,7: 1475-1480.

(3) Yuan Zhong-Yu, Dai Ting ,Wang Shu-Sen, Peng Rou-Jun, Li Xing-Hua, Qin, Tao, Song Li-Bing, Wang Xi, Overexpression of ETV4 protein in triple-negative breast cancer is associated with a higher risk of distant metastasis. OncoTargets and Therapy,2014,7:1733-1742.

(4) Luo Rong-Zhen, Yuan Zhong-Yu, Li Mei, Xi Shao-Yan, Fu Jia, He Jiehua(*), Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer.,OncoTargets and Therapy,2013,6:883-888.

(5) Qin Tao, Yuan Zhongyu, Peng Roujun, Bai Bing, Shi Yanxia, Teng Xiaoyu, Liu Donggeng, Wang Shusen(*), HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients.,OncoTargets and Therapy,2013,6:341-347.

(6) Dong Min,Wan, Xiang-bo, Yuan Zhong Yu, Wei Li Fan, Xin Juan Wang, Tian-tian Lv, Yan Chun Li, Xing Chen, Zhan-hong Chen, Jie Lin, Qu Wen, Jing-yun Ma, Xiao-kun, Liu Quentin(*), Wu Xiang Yuan(*), Low expression of Beclin 1 and elevated expression of HIF-1alpha refine distant metastasis risk and predict poor prognosis of ER-positive, HER2-negative breast cancer.,Medical Oncology,2013,30(1):355-355.

(7) Qin T. Yuan ZY, Peng RJ, Zeng YD, Shi YX, Teng XY, Liu DG, Bai B, Wang SS(*), Efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer: A retrospective analysis,Current Oncology,2013,20(4):196-204.

(8) Xue Cong, Peng Roujun, Cao Ye, Wang Shusen, Shi Yanxia, An Xin, Xu Fei, Yuan Zhongyu(*), Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer.,PLos One,2016,11(2):e0148849-e0148849.

(9) Qin Tao, Zeng Yin-duo, Qin Ge, Xu Fei, Lu Jia-bin, Fang Wen-feng, Xue Cong, Zhan Jian-hua, Zhang Xin-ke, Zheng Qiu-fan, Peng Rou-jun, Yuan Zhong-yu(*), Zhang Li(*), Wang Shu-sen(*), High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.,Oncotarget,2015,6(32):33972-33981.

(10) Xue Cong, Peng RouJun, Wang ShuSen, Shi YanXia, An, Xin, Xu Fei, Yuan Zhong Yu(*), Operable breast cancer of the inner hemisphere is associated with poor survival.,Journal of Breast Cancer,2015,18(1):36-43.

(11) Li Xinghua, Liang Weijiang, Liu Junling, Lin Chuyong, Wu, Shu, Song Libing, Yuan Zhongyu(*), Transducin (ss)-like 1 X-linked receptor 1 promotes proliferation and tumorigenicity in human breast cancer via activation of beta-catenin signaling.,Breast Cancer Research,2014,16(5):465-465.

(12) Xu Jie, Wu Xing, Zhou Wei-hua, Liu An-wen, Wu Jian-bing, Deng Jin-yun, Yue Cai-feng, Yang Shao-bing, Wang Jing, Yuan Zhong-yu(*), Liu Quentin(*), Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer.,PLos One,2013,8(2):e56919-e56919.

(13) He Jie-Hua, Luo Rong-Zhen, Cai Mu-Yan, Li Mei, Lu Jia-Bing, Yuan Zhong-Yu(*), Decreased expression of light chain 3 (LC3) increased the risk of distant metastasis in triple-negative breast cancer.,Medical Oncology,2013,30(1):468-468.

(14) Fang Wang, Wenzhuo He, Huijuan Qiu, Xi Wang, Guifang Guo, Xuxian Chen, Yuming Rong, Feifei Zhou, Chenxi Yin, Zhongyu Yuan(*), Liangping Xia(*), Lymph Node Ratio and pN Staging Show Different Superiority As Prognostic Predictors Depending on the Number of Lymph Nodes Dissected in Chinese Patients With Luminal A Breast Cancer,Clinical Breast Cancer,2012,12(6):404-411.

(15) Xue Cong, Wang Xi, Peng Roujun, Shi Yanxia, Qin Tao, Liu Donggen, Teng Xiaoyu, Wang Shusen, Zhang Li(*), Yuan Zhongyu(*), Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China.,Cancer Science,2012,103(9):1679-1687.

(16) He Jiehua,Peng Roujun,Wang Shusen, Yuan Zhongyu(*), Peng Jiewen, Lin Guinan, Jiang Xiaomei, Qin Tao, Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray.,Medical Oncology,2012,29(2):406-410.

(17) Wang Shusen, Shi Yanxia, Wang Xi, Liu Donggen, Yuan Zhongyu(*), Peng Roujun, Teng Xiaoyu, Qin Tao, Peng Jiewen, Lin Guinan,Jiang Xiaomei, Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.,Medical Oncology,2012,29(2):547-553.

(18) Liu Donggen, He Jiehua, Wang Shusen, Peng Roujun, Shi Yanxia, Teng Xiaoyu, Qin Tao, Yuan Zhongyu(*), EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray.,Medical Oncology,2012,29(2):401-405.

(19) Wang Xi,Wang Shu-Sen,Peng Rou-Jun,Qin Tao,Shi Yan-Xia,Teng Xiao-Yu,Liu Dong-Gen, Chen Wei-Qing, Yuan Zhong-Yu(*), Interaction of coping styles and psychological stress on anxious and depressive symptoms in Chinese breast cancer patients.,Asian Pac J Cancer Prev,2012,13(4):1645-1649.

(20) Roujun Peng,Shusen Wang,Yanxia Shi,Donggen Liu,Xiaoyu Teng,Tao Qin,Yixin Zeng(*),Zhongyu Yuan(*),Patients 35 years old or younger with operable breast cancer are more at risk for relapse and survival: A retrospective matched case–control study,Breast,2011,20(6):568-573.

(21) Liu Dong-Gen, Wang Shu-Sen, Peng Rou-Jun, Qin Tao, Shi Yan-Xia, Teng Xiao-Yu, Wang Xi, Chen Wei-Qing, Yuan Zhong-Yu(*), Interaction of social support and psychological stress on anxiety and depressive symptoms in breast cancer patients.,Asian Pac J Cancer Prev,2011,12(10):2523-2529.

(22) Zhang Liang, Ding Ya, Liu Junling, Sun Jian, Yuan Zhongyu, Lei Fangyong, Wu Shu, Li Su, Zhang Dongsheng(*), MicroRNA-500 sustains nuclear factor-kappaB activation and induces gastric cancer cell proliferation and resistance to apoptosis.,Oncotarget,2015,6(4):2483-2495.

(23) Zou Zhengzhi, Zhang Qiongxia, Long Zijie, Chen, Yuan Zhongyu Jinna Tang, Zhiping Zhu Yuliang, Chen Shupeng, Xu Jie, Yan Min, Wang Jing, Liu Quentin(*), Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells.,Autophagy,2012,8(12):1798-1810.

(24) Shi Yan-Xia, Xia Qing, Peng Rou-Jun, Wang Shu-Sen, Yuan Zhong-Yu, An Xin, Cao Ye, Tan Yu-Ting, Jin Ying, Cai Xiu-Yu, Sun Yue-Li, Teng Xiao-Yu, Liu Dong-Geng(*), Jiang Wen-Qi(*), Comparison of clinicopathological characteristics and prognoses between bilateral and unilateral breast cancer.,Journal of Cancer Research and Clinical Oncology,2012,138(4):705-714.

(25) Shi Yan-Xia ,Tan Yu-Ting, Yuan Zhong-Yu, Wang Shu-Sen, Peng Rou-Jun, An Xin, Cao Ye, Jin Ying, Cai Xiu-Yu, Sun Yue-Li, Teng Xiao-Yu, Liu, Dong-Geng(*), Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer.,Medical Oncology,2012,29(1):39-47. 

出诊时间： 周二上午，周五上午（特需）（具体以当天公示为准）